Clinical Trials Industry News More

  1. Icagen Announces Lifting Of Partial Clinical Hold Of ICA-105665 8/4/2009
    Icagen, Inc. (Nasdaq:ICGN) reported today that the FDA has lifted the partial clinical hold related to the development of ICA-105665, the Company's novel orally available small molecule KCNQ potassium channel agonist, for the treatment of epilepsy.
  2. Avastin Approved In US For The Most Common Type Of Kidney Cancer 8/4/2009
    Avastin is designed to block the vascular endothelial growth factor (VEGF) protein to address a key underlying cause of cancer growth. Avastin works differently than other approved medicines for renal cell carcinoma because it specifically binds to the VEGF protein, which is produced in elevated amounts in most kidney cancers.
  3. Position Paper Highlights Advancements In Balance Enclosure Technology 8/3/2009
    Labconco Corporation offers an 8-page white paper titled, “Advances in Balance Enclosure Technology Bring Safety Enhancements to the Pharmaceutical Industry.”
  4. European Commission Approves Broader Label For Avastin Allowing Combination With Docetaxel For The First-Line Treatment Of Advanced (Metastatic) Breast Cancer 7/30/2009
    More patients with advanced breast cancer could benefit from Avastin as a result of a broader label allowing Avastin to be combined with both docetaxel or paclitaxel chemotherapy, Roche announced recently. In March 2007, Avastin was approved in Europe for the first-line treatment of patients with advanced breast cancer, in combination with paclitaxel.
  5. Cardiome Achieves Milestone From Collaboration With Merck & Co., Inc. 7/30/2009
    Cardiome Pharma Corp. recently announced that it has earned a US$15M milestone payment from its collaboration with Merck & Co., Inc., through an affiliate. The milestone was triggered by the submission, by Merck, of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) seeking marketing approval for vernakalant (iv) in the European Union.
  6. M2S Announces New Clinical Trial Product, iMAS, A Medical Image Collect And Hold Solution 7/30/2009
    M2S Inc., a global provider of image management services for biopharmaceutical and medical device clinical trials, today announced that it has launched a new product to collect and hold medical images in clinical trials, called iMAS (Image Management Archive System).
  7. Transformational Transaction Establishes Agilent's Position As A Leading Provider Of Analytical Instrumentation To The Applied And Life Sciences Markets 7/29/2009
    Agilent Technologies Inc. and Varian Inc. recently announced that they have signed a definitive agreement for the acquisition by Agilent of Varian, a leading worldwide supplier of scientific instrumentation and associated consumables for life science and applied market applications.
  8. Generex Publishes Results From Pre-Clinical Studies On Immunotherapeutic Vaccine For HPV-Induced Cervical Cancer 7/23/2009
    Generex Biotechnology Corporation announced today publication of studies demonstrating the anti-cancer activity of a novel Ii-Key/HPV immunotherapeutic vaccine.
  9. Clinical Research Safety And Ethical Standards In Developing World Up To U.S. Levels 7/23/2009
    Clinical trials conducted in the developing world meet the same safety, ethical and quality standards as those conducted in the developed world. That is the conclusion of a major report released recently by the Association of Clinical Research Organizations (ACRO).
  10. Abbott And GSK To Collaborate On Molecular Diagnostic Test To Select Candidate Patients For Future Cancer Immunotherapy 7/14/2009
    Abbott announced recently that it has entered into an agreement with GlaxoSmithKline (GSK) to develop an automated molecular diagnostic test, based on polymerase chain reaction (PCR) technology, intended to screen non-small cell lung cancer (NSCLC) tumors for expression of the MAGE-A3 antigen.